Marc-Antoine Jegonday
Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes
Papers
2
Total Citations
33
H-Index
2
About
Marc-Antoine Jegonday is a leading urologic oncologist whose research focuses on advancing minimally invasive treatments for renal cell carcinoma, particularly through thermal ablation and robotic-assisted surgery. His major contributions center on comparative effectiveness studies that challenge existing treatment paradigms for T1b renal tumors. His landmark multicenter matched-pair analysis, the AblatT1b study (UroCCR 80), directly compared percutaneous tumor ablation with robotic-assisted partial nephrectomy, providing crucial evidence that thermal ablation offers comparable oncologic outcomes with potentially lower morbidity for larger renal masses. This work, published in 2023 and accumulating over 30 citations across its companion papers, has helped reshape clinical decision-making for patients with cT1b disease. Jegonday’s research is notable for its rigorous methodology, employing matched-pair analysis to minimize selection bias, and for integrating emerging 3D image-guided robotic techniques. His findings have significant implications for expanding ablation eligibility beyond small renal masses, offering patients less invasive options without compromising cancer control. Through these contributions, Jegonday continues to influence the evolution of nephron-sparing surgery and ablation strategies in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2